This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Semen Strychni (SS)

Authoring team

Semen Strychni (SS)

  • the dried seeds of Strychnos nux-vomica L. (Loganiaceae), is bitter and warm and, according to the TCM (Traditional Chinese Medicine) theory, belongs to the liver and spleen meridians (1,2)
    • dry mature seeds are disc-shaped, slightly concave, and hard
    • SS was first recorded in the Compendium of Materia Medica in Ming Dynasty and is now collected by the Chinese pharmacopeia

  • SS can be used to treat rheumatoid arthritis, facial nerve paralysis, amyotrophic lateral sclerosis and Myasthenia Gravis (MG) (1,2)
    • the main toxic component of SS is strychnine
    • alkaloids have been found to be the main active ingredient in SS, which includes strychnine, brucine and other nitrogen oxides

Reference:

  1. Fang P et al. Study on the Potential Mechanism of Semen Strychni against Myasthenia Gravis Based on Network Pharmacology and Molecular Docking with Experimental Verification. Evid Based Complement Alternat Med. 2022 Oct 1;2022:3056802.
  2. Tang X et al. Exploring the mechanism of Semen Strychni in treating amyotrophic lateral sclerosis based on network pharmacology. Medicine (Baltimore). 2023 Sep 8;102(36):e35101.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.